New Study Will Examine Additional Health and Economic Benefits for People with Type 2 Diabetes When Personalized Wellness Technologies Are Paired with a Smart Blood Glucose Ecosystem – Yahoo Finance

Share Article

LifeScan to launch ECLIPSE study to further explore A1C reduction and cost savings when patients use OneTouch® blood glucose data with digital wellness solutions from Noom®, Fitbit®, Welldoc® or Cecelia Health®
MALVERN, Pa., May 18, 2022 /PRNewswire/ — LifeScan, a world leader in blood glucose monitoring, today announced recruitment for a new study that will evaluate the clinical and economic value of using the digital health subscriptions offered through OneTouch® Solutions for people with type 2 diabetes. Launched in the U.S. in October 2021, OneTouch Solutions is a digital one-stop shop that offers a variety of personalized wellness solutions from proven experts Noom, Fitbit, Welldoc and Cecelia Health, offering live and digital diabetes support, assistance reaching weight and fitness goals, and much more. ECLIPSE (formally "Evidence for Health Improvement in People with Diabetes Using OneTouch & Partner Solutions") will evaluate if using the OneTouch Reveal® app with the OneTouch® Verio Reflect meter and one of the proven offerings from these partners can lead to better diabetes management like A1C reductions and cost savings.
"Research has shown that proven digital health and wellness tools and virtually-accessed expert guidance can ease the burden of diabetes management," said Dr. Elizabeth Holt, Head of Global Medical, Clinical, and Safety, LifeScan. "It is our belief that combining OneTouch blood glucose monitoring data with one of these proven health applications will deliver further benefits to patients, and this study aims to validate that hypothesis."
"This study has the potential to offer tremendous value and insights around having a more integrated whole-health approach to diabetes management," said Dr. Steven V. Edelman, founder and director of Taking Control of Your Diabetes1. "Digital interventions such as the ones being assessed are already being embraced so it makes sense to look at their value when combined with a smart blood glucose meter."
The study aims to recruit 800 people with type 2 diabetes, with four study arms of 200 participants each focused on a different solution:
Noom: a psychology-based weight and wellness program, which includes education, tools, and coaching to help people with type 2 diabetes adopt healthier habits, lose weight, and improve blood glucose control
Fitbit: uses the Fitbit Inspire 2 tracker to provide activity and wellbeing insight to give users a more complete view of how lifestyle factors, like daily activity, nutrition and sleep can impact blood glucose levels
Welldoc: offers personalized, AI-driven health coaching on multiple health conditions, namely prediabetes, diabetes, hypertension and heart failure
Cecelia Health: provides one-on-one virtual support for diabetes management and other health concerns, needs, and questions delivered by Certified Diabetes Care and Education Specialists
Study enrollment will begin on May 26, 2022.
About LifeScan
LifeScan is a global leader in blood glucose monitoring and digital health technology and has a vision to create a world without limits for people with diabetes and related conditions. More than 20 million people and their caregivers around the world count on LifeScan's OneTouch brand products to manage their diabetes. Together, LifeScan and OneTouch improve the quality of life for people with diabetes with products and digital platforms defined by simplicity, accuracy, and trust. and
1 Taking Control of Your Diabetes (TCOYD), a Nonprofit Charitable Educational Organization, is partnering with LifeScan to provide recruitment support for the ECLIPSE ("Evidence for Health Improvement in People with Diabetes Using OneTouch & Partner Solutions") study.
The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by LifeScan Scotland Ltd. and its affiliates is under license.
View original content to download multimedia:
SOURCE Lifescan, Inc.
Option exercised as one case confirmed in Massachusetts and six more are being monitored.
Even though it seems like only yesterday people were calculating the date they could feel fully protected by their COVID-19 vaccination, boosters are increasingly being recommended for wider swaths of the population.In fact, now a second booster is an option for many Americans. Recently, the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) authorized a second booster shot of the Pfizer-BioNTech and Moderna vaccines for everyone 50 and older and for peop
Shares of Emergent BioSolutions were rising sharply Thursday. The drugmaker produces a vaccine that can help prevent people from getting monkeypox. The U.S. confirmed a case of monkeypox on Wednesday in a man in Massachusetts who recently traveled to Canada.
With that as a backdrop, let's consider two biotech stocks that don't grab a lot of headlines but deserve serious consideration: Incyte (NASDAQ: INCY) and Axsome Therapeutics (NASDAQ: AXSM). Incyte is a drugmaker with a particular focus on the field of oncology. Its best-selling product is called Jakafi, which treats some types of bone marrow cancer, among other conditions.
The 26-year-old TikTok star opened up to her followers about her eating disorder and why she's seeking treatment.
OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary technology, today announced new data supporting the safety and efficacy of its SavvyWire recently approved by Health Canada for transcatheter aortic valve replacement (TAVR) procedures. The results of the 20 patient first-in-human clinical study of the SavvyWire were presented earlier today at the 2022 EuroPCR conference, and simu
Dr. Yashica Robinson, Board member of Physicians for Reproductive Health and the director of the Alabama Women’s Wellness Center testified today in front of the House Judiciary Committee hearing to examine abortion access and care across the country. Robinson is the head of one of the last few abortion clinics in her state. While speaking before the committee Robinson emphasized the importance of abortion as essential health care.
If it is OK to mock one of the most privileged people in the world on account of them being autistic, then what hope do the rest of us ‘regular’ folk have?
Shares of Enanta Pharmaceuticals Inc. slid 19.3% in premarket trading on Thursday, the day after the company said its experimental treatment for respiratory syncytial virus did not meet the primary endpoint in a Phase 2b clinical trial. The therapy did not reduce symptoms when compared to placebo; however, the company said there was a statistically significant difference in the number of adult patients that reported undetectable RNA at day five of treatment. "Moving forward, our broad clinical d
“You need to get husband, wake up your son, you need to put him in the car and take him to Children’s Healthcare of Atlanta immediately,” the doctor told her.
‘Tell me you live in America without telling me that you live in America’
We have made huge strides in research across lung cancer types, stages and patient groups
The mental-health startup said it named David Mou as its new chief executive officer, as the company faces a federal probe of its prescribing practices.
Alison Holland, 64, of Gloucestershire, says she married teacher Bert Holland, 69, thinking they had escaped the “curse” of Huntington’s disease
U.S.-listed shares of Zealand Pharma soared 21.2% in premarket trading on Thursday after the company said a Phase 3 clinical trial evaluating its investigational treatment for babies with a rare genetic disorder met the primary endpoint. Zealand is testing dasiglucagon as a treatment for pediatric patients with congenital hyperinsulinism, which causes excess insulin secretion and low blood sugar. The company said it plans to discuss submitting a new drug application to the Food and Drug Administ
Merck stock has reinvigorated on the company's plans in heart disease. Will its efforts be enough as Keytruda goes off patent?
Here's what you should know about the monkeypox virus. Health officials say there is no threat to the public.
The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more.
It is the most succinct and dispassionate name for long COVID: U09.9 — a medical diagnostic code created last year to allow doctors to document post-COVID conditions. Now a large new study has analyzed data from the first few months after the code took effect, and the results paint a sobering picture of long COVID’s serious and ongoing impact on people’s health and the U.S. health care system. Long COVID, a complex constellation of lingering or newly emerging symptoms that can last for months or
A smattering of monkeypox cases in Britain has prompted authorities to offer a smallpox vaccine to some healthcare workers and others who may have been exposed, as a handful more cases were confirmed in parts of Europe. Monkeypox is a usually mild viral illness, characterised by symptoms of fever as well as a distinctive bumpy rash. First identified in monkeys, the viral disease typically spreads through close contact and largely occurs in west and central Africa.


You might also like

Surviving 2nd wave of corona

Surviving The 2nd Wave of Corona

‘This too shall pass away’ this famous Persian adage seems to be defeating us again and again in the case of COVID-19. Despite every effort